Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women

Anti Aging Clinical Trial

— Pharmanex  

Official title:

A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Center Study on the Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01598272
• Other study ID #: 11-PHX-03-NU-01
• Status: Completed
• Phase: Phase 4
• First received: May 8, 2012
• Last updated: December 10, 2014
• Start date: July 2011
• Est. completion date: June 2012

Study information

• Verified date: December 2014
• Source: Pharmanex
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Determine the effects of 8 week Investigational Supplement on cellular detoxification and gene expression profiles

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 35 Years to 73 Years

Eligibility

Inclusion Criteria:

1. Females aged 35-73 years

2. Signed informed consent

3. BMI between 23 and 35 kg/m2

4. A resting normotensive blood pressure is defined as a systolic blood pressure between 90-145 mmHg and a diastolic blood pressure of 50 90 mmHg

5. BioPhotonic scanner score below 30,000

6. Use of effective method of contraception by females of childbearing [potential and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study]. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; or any double barrier method. Women who have had a hysterectomy or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal for at least 1 year prior to Visit 1 are not considered to be of childbearing potential.

7. Ability to speak and understand English.

8. Willing to consume one high-fat high carbohydrate meal at the last visit consisting of 1 McDonald's egg Mcmuffin with cheese (no meat), 1 Sausage McMuffin with cheese (no egg), 2 hashbrowns, 1 12 oz Coke Cola or Sprite.

9. Willing to not exercise the morning of your last visit

Exclusion Criteria:

1. Self-reported chronic condition that may affect subject safety (e.g., diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g., chronic fatigue)

2. Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the course of the study.

3. Antihypertensive medication use.

4. Allergies to any ingredients contained in the Investigational Product.

5. Consumption of more than 600 mg of caffeine from all sources per day (equivalent to 24 oz. caffeinated coffee, 96 oz. of soda, 60 oz. of tea, 60 oz. energy drinks , or a combination thereof).

6. Consumption of herbal supplement known to affect energy levels (e.g., ginseng, cordyceps, licorice, Lycium, pomegranate, etc.).

7. Consumption of any of the supplements included in the formulas (Cordyceps sinensis, Panax Ginseng extract, pomegranate extract, red orange complex, grape seed extract or broccoli seed extract).

8. Known iron deficiency anemia.

9. Treatment for insomnia or depression within 30-days prior to the screening visit.

10. Recently started taking medication known to effect energy (e.g., thyroid medication). If taking medication (e.g., thyroid medication), must be stable for at least four months.

11. Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days prior to the screening visit.

12. Planned surgical procedure during the course of the study.

13. Currently participating in another study or have done so within 30 days prior to the screening visit or is likely to enroll in another clinical or nutritional study.

14. Any laboratory value that the investigator deems clinically significant.

15. Currently participating in a weight loss program or planning to go on a weight loss diet during the course of the study.

16. Allergies to egg or dairy products, Vegetarian or unwilling to consuming sausage.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Anti Aging

Intervention

Dietary Supplement:
• Vitality product AM + Vitality product PM
Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
• Placebo
Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days

Locations

Country	Name	City	State
United States	Aspen Clinical Research	Orem	Utah

Sponsors (2)

Lead Sponsor	Collaborator
Pharmanex	Aspen Clinical Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine effects of investigational supplement on gene expression profiles.	Gene Expression Panel (microarray PBMCs), Inflammatory Panel, Oxidative stress Markers-including glutathione panel and F2 isoprostane, Anti-oxidant panel, and Lipid Panel	Day 0, Day 28, Day 56	No
Secondary	Establish a safety profile of investigational supplement	Measure number of participants with adverse events. Fasted Safety Labs (chemistry, hematology, Coagulation)compared to baseline.	Day 0, Day 28, Day 56	Yes
Secondary	Determine effects of investigational supplement on markers of inflammation		Day 0, Day 28, Day 56	No
Secondary	Determine effects of investigational supplement on composite cognitive index		Day 0, Day 28, Day 56	No
Secondary	Determine changes in scoring on HADS assessment (Hospital Anxiety & Depression Scale)	Questionnaire: Hospital Anxiety and Depression Scale (HADS)	Day 0, Day 28, Day 56	No
Secondary	Determine changes in Quality of Life	SF-36 (Quality of Life Assessment)	Day 0, Day 28, Day 56	No
Secondary	Determine changes in sleep patterns and quality	Sleep measurement scale.	Day 0, Day 28, Day 56	No
Secondary	Determine changes to overall health	Abbreviated Physical Exam	Day 0, Day 28, Day 56	No
Secondary	Determine changes to biological age scanning (Digital Pulse Wave Analyzer (DPA)	Digital Pulse Wave Analyzer	Day 0, Day 28, Day 56	No
Secondary	Determine changes in Biophotonic Scanner Scores	Measure antioxidants in the palm of the skin.	Day 0, Day 28, Day 56	No
Secondary	Determine changes in skin advanced glycation endproducts (AGE) levels	AGE Reader	Day 0, Day 28, Day 56	No